Tebo J M, Mortensen R F
Department of Microbiology, Ohio State University, Columbus 43210-1292.
J Immunol. 1990 Jan 1;144(1):231-8.
Human C-reactive protein (CRP) is an acute phase reactant that is opsonic and an activator of macrophage tumoricidal function. CRP also activates the classical C cascade. These activities suggest that CRP might interact with monocytes/macrophages via specific receptors in a manner analogous to the interaction of IgG with FcR. With the use of radio-labeled human CRP, we have observed specific binding of CRP to human blood monocytes and the human monocytic cell line U-937. Binding was saturable at a pathophysiologic concentration of CRP, with an estimated KD of 9.5 x 10(-8) M and 3.6 x 10(5) binding sites/cell. Specific binding was inhibited by polyclonal human IgG as well as an IgG1 myeloma. In the converse experiment, CRP failed to inhibit specific [125I]IgG binding. The mAb IV.3, which inhibits binding of IgG immune complexes to FcRII, did not inhibit CRP binding. A 100-fold excess of phosphorylcholine or the phosphorylcholine binding peptide of CRP (residues 47-63) failed to inhibit binding. Although human rIFN-gamma and PMA increased FcRI expression, these reagents had no affect on CRP receptor expression. A single membrane protein of 38 to 41 kDa from U-937 cells was chemically cross-linked to [125I]CRP; the cross-linking was inhibited by human IgG1 but not the IV.3 mAb. Furthermore, two membrane proteins with a Mr of 38 to 40 kDa and 58 to 60 kDa were isolated by CRP ligand-affinity chromatography. These proteins were of a distinct size from those isolated for FcRI from an IgG ligand matrix. These studies demonstrate specific binding of human CRP to a human monocytic cell line via receptors that are distinct from the IgG FcR and implicate CRP in nonspecific, preimmune host defense reaction mediated by cells of the monocytic lineage.
人C反应蛋白(CRP)是一种急性期反应物,具有调理作用且是巨噬细胞杀肿瘤功能的激活剂。CRP还能激活经典补体级联反应。这些活性表明CRP可能通过特定受体与单核细胞/巨噬细胞相互作用,其方式类似于IgG与FcR的相互作用。通过使用放射性标记的人CRP,我们观察到CRP与人血单核细胞及人单核细胞系U-937有特异性结合。在生理病理浓度的CRP下,结合具有饱和性,估计解离常数(KD)为9.5×10⁻⁸ M,每个细胞有3.6×10⁵个结合位点。多克隆人IgG以及IgG1骨髓瘤可抑制特异性结合。在反向实验中,CRP未能抑制特异性[¹²⁵I]IgG结合。抑制IgG免疫复合物与FcRII结合的单克隆抗体IV.3不抑制CRP结合。100倍过量的磷酰胆碱或CRP的磷酰胆碱结合肽(第47 - 63位氨基酸残基)未能抑制结合。虽然人重组干扰素γ(rIFN-γ)和佛波酯(PMA)可增加FcRI表达,但这些试剂对CRP受体表达无影响。U-937细胞中一个38至41 kDa的单一膜蛋白与[¹²⁵I]CRP发生化学交联;人IgG1可抑制这种交联,但单克隆抗体IV.3不能。此外,通过CRP配体亲和层析分离出两个分子量分别为38至40 kDa和58至60 kDa的膜蛋白。这些蛋白的大小与从IgG配体基质中分离出的FcRI不同。这些研究证明人CRP通过与IgG FcR不同的受体与人单核细胞系发生特异性结合,并表明CRP参与由单核细胞系细胞介导的非特异性、免疫前宿主防御反应。